You just read:

Phase II Study Results Showed Eisai's E7080 (Lenvatinib [USAN]) Demonstrated an Objective Response Rate of 59% in Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer[1]

News provided by

Eisai Europe Ltd

01 Jun, 2011, 16:00 BST